» Articles » PMID: 33827078

Epidemiology of COVID-19 Infection in Hospitalized End-Stage Kidney Disease Patients in a Predominantly African-American Population

Overview
Journal Am J Nephrol
Publisher Karger
Specialty Nephrology
Date 2021 Apr 7
PMID 33827078
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Background: End-stage kidney disease patients on dialysis are particularly susceptible to COVID-19 infection due to comorbidities, age, and logistic constraints of dialysis making social distancing difficult. We describe our experience with hospitalized dialysis patients with COVID-19 and factors associated with mortality.

Methods: From March 1, 2020, to May 31, 2020, all dialysis patients admitted to 4 Emory Hospitals and tested for COVID-19 were identified. Sociodemographic information and clinical and laboratory data were obtained from the medical record. Death was defined as an in-hospital death or transfer to hospice for end-of-life care. Patients were followed until discharge or death.

Results: Sixty-four dialysis patients with COVID-19 were identified. Eighty-four percent were African-American. The median age was 64 years, and 59% were males. Four patients were on peritoneal dialysis, and 60 were on hemodialysis for a median time of 3.8 years, while 31% were obese. Fever (72%), cough (61%), and diarrhea (22%) were the most common symptoms at presentation. Thirty-three percent required admission to intensive care unit, and 23% required mechanical ventilation. The median length of stay was 10 days, while 11 patients (17%) died during hospitalization and 17% were discharged to a temporary rehabilitation facility. Age >65 years (RR 13.7, CI: 1.9-100.7), C-reactive protein >100 mg/dL (RR 8.3, CI: 1.1-60.4), peak D-dimer >3,000 ng/mL (RR 4.3, CI: 1.03-18.2), bilirubin >1 mg/dL (RR 3.9, CI: 1.5-10.4), and history of peripheral vascular disease (RR 3.2, CI: 1.2-9.1) were associated with mortality. Dialysis COVID-19-infected patients were more likely to develop thromboembolic complications than those without COVID-19 (RR 3.7, CI: 1.3-10.1).

Conclusion: In a predominantly African-American population, the mortality of end-stage kidney disease patients admitted with COVID-19 infection was 17%. Age, C-reactive protein, D-dimer, bilirubin, and history of peripheral vascular disease were associated with worse survival.

Citing Articles

Predictors of Mortality among End-Stage Renal Disease Patients with COVID-19 Admitted in a Philippine Tertiary Government Hospital: A Retrospective Cohort Study.

Suaybaguio S, Jamias J, Briones M Acta Med Philipp. 2025; 58(22):44-51.

PMID: 39817110 PMC: 11732597. DOI: 10.47895/amp.vi0.8374.


Incorporation of Chest Computed Tomography Quantification to Predict Outcomes for Patients on Hemodialysis with COVID-19.

Xing H, Gu S, Li Z, Wei X, He L, Liu Q Kidney Dis (Basel). 2024; 10(4):284-294.

PMID: 39131882 PMC: 11309758. DOI: 10.1159/000539568.


Impact of the COVID-19 Pandemic on the Provision of Dialysis Service and Mortality in Veterans Receiving Maintenance Hemodialysis in the VA: An Interrupted Time-Series Analysis.

Patel S, Trujillo Rivera E, Raman V, Faselis C, Wang V, Fink J Am J Nephrol. 2023; 54(11-12):508-515.

PMID: 37524062 PMC: 10959175. DOI: 10.1159/000532105.


Clinical manifestations of COVID-19 infection in dialysis patients and protective effect of COVID-19 vaccine.

Zhang X, Chen Q, Xu G Inflamm Res. 2023; 72(5):989-1000.

PMID: 37004547 PMC: 10066982. DOI: 10.1007/s00011-023-01723-1.


Risk of COVID-19 and Cost Burden in End-Stage Renal Disease Patients and Policy Implications for Managing Nephrology Services during the COVID-19 Pandemic.

Behlul S, Ozdal M Healthcare (Basel). 2022; 10(12).

PMID: 36553874 PMC: 9777726. DOI: 10.3390/healthcare10122351.


References
1.
Lassila R, Peltonen S, Lepantalo M, Saarinen O, Kauhanen P, Manninen V . Severity of peripheral atherosclerosis is associated with fibrinogen and degradation of cross-linked fibrin. Arterioscler Thromb. 1993; 13(12):1738-42. DOI: 10.1161/01.atv.13.12.1738. View

2.
Norris K, Williams S, Rhee C, Nicholas S, Kovesdy C, Kalantar-Zadeh K . Hemodialysis Disparities in African Americans: The Deeply Integrated Concept of Race in the Social Fabric of Our Society. Semin Dial. 2017; 30(3):213-223. PMC: 5418094. DOI: 10.1111/sdi.12589. View

3.
Stefan N, Birkenfeld A, Schulze M, Ludwig D . Obesity and impaired metabolic health in patients with COVID-19. Nat Rev Endocrinol. 2020; 16(7):341-342. PMC: 7187148. DOI: 10.1038/s41574-020-0364-6. View

4.
Abbott K, Glanton C, Trespalacios F, Oliver D, Ortiz M, Agodoa L . Body mass index, dialysis modality, and survival: analysis of the United States Renal Data System Dialysis Morbidity and Mortality Wave II Study. Kidney Int. 2004; 65(2):597-605. DOI: 10.1111/j.1523-1755.2004.00385.x. View

5.
Kalantar-Zadeh K, Abbott K, Salahudeen A, Kilpatrick R, Horwich T . Survival advantages of obesity in dialysis patients. Am J Clin Nutr. 2005; 81(3):543-54. DOI: 10.1093/ajcn/81.3.543. View